{"id":4406,"date":"2020-08-26T09:19:53","date_gmt":"2020-08-26T09:19:53","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/125-oh2-vitamin-d-elisa\/"},"modified":"2020-08-26T09:20:21","modified_gmt":"2020-08-26T09:20:21","slug":"125-oh2-vitamin-d-elisa","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/125-oh2-vitamin-d-elisa\/","title":{"rendered":"1,25 (OH)2 Vitamin D ELISA"},"content":{"rendered":"<p>The hormone 1,25 dihydroxy vitamin D is formed in the kidney and has important functions in calcium metabolism; hence impaired kidney function can result in a decrease in 1,25 dihydroxy vitamin D levels and the development of renal osteopathy, which is characterized by osteomalacia and osteitis fibrosa. This company\u2019s assay development programme is focusing specifically on new vitamin D assays. After the recent launch of the 25-Hydroxyvitamin D Total RIA and ELISA assays based on patented monoclonal antibodies manufactured in-house, a new easy-to-use 1,25 dihydroxy Vitamin D ELISA is launched. This ELISA is specifically designed to be used manually as well as on open automated systems. As the total assay time is less than 6 hours, the patient\u2019s results will be available the same day. The assay has been validated on the Stratec GEMINI open ELISA automated analyser (Stratec Biomedical GMBH \u2013 Germany) and a validated protocol will be made available to all Stratec GEMINI users.<br \/>\n<!--more--><br \/>\n<strong>Supplier:<\/strong> DIAsource ImmunoAssays<br \/>\n<strong>Website:<\/strong> <a href=\"\" target=\"_blank\" rel=\"noopener noreferrer\"><\/a><\/p>\n<p><a class=\"avia-button avia-color-theme-color\" href=\"mailto:Joelle.Bock@diasource.be\">Mail the supplier<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The hormone 1,25 dihydroxy vitamin D is formed in the kidney and has important functions in calcium metabolism; hence impaired kidney function can result in a decrease in 1,25 dihydroxy vitamin D levels and the development of renal osteopathy, which is characterized by osteomalacia and osteitis fibrosa. This company\u2019s assay development programme is focusing specifically [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":10178,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/4406"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=4406"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/4406\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/10178"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=4406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=4406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=4406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}